Novel Cancer Therapy Based On A Telomerase Reverse Transcriptase Variant

Invention Summary:

Telomeres, the protein-DNA structures located on the ends of eukaryotic chromosomes, are required for chromosome stability during DNA replication. Studies have demonstrated that telomere length may serve to limit the replication potential of cells, hence serve as a barrier to immortalization and carcinogenesis. Telomerase plays a key role in maintaining telomere function and activity by catalyzing telomere replication. In human, telomerase activation is observed in 90% of all tumors. Therefore, telomerase is a bona fide target for development of agents directed to cancer therapy.

The inventors have generated a novel mutant of human telomerase catalytic core (LAhTERT). Forced expression of LAhTERT in prostate cancer, cervical carcinoma, and squamous carcinoma cell lines results in a delay in cell cycle progression and renders cells more sensitive to mitochondrial DNA damage and apoptosis induced by oxidative stress (which may be induced by H2O2, radiation, and other genotoxic agents). Targeted delivery of LAhTERT may be achieved by linking LAhTERT peptides or expression vectors with antibodies or nanoparticles that specifically target cancer cells or other desired cell types.

Market Applications:

  • Treatment for cancer and other hyperplasia diseases
  • Treatment for inflammatory and autoimmune diseases

Intellectual Property & Development Status:

United States Patent Number 8,362,209 granted on January 29, 2013

Rutgers ID: S07-28
Category(s):
Life Sciences
Research Tools
Contact:
Yong Zhang
Licensing Manager
848-932-4523
yong.zhang@rutgers.edu
Inventors:
Janine Santos
Keywords:
Autoimmune
Biomaterials
Oncology